Ki-67对弥漫大B细胞淋巴瘤预后评估的意义

尚晋; 陈志忠; 魏天南; 陈为民

doi:10.13201/j.issn.1004-2806.2012.04.012

Ki-67对弥漫大B细胞淋巴瘤预后评估的意义

- 1 福建省立医院血液科(福州, 350001);
- 2 福建省立医院病理科

详细信息

通讯作者: 陈为民,E-mail:chenweiming@medmail.com.cn

中图分类号: R733.4

收稿日期: 2011-07-20

Prognostic value of Ki-67 protein in patients with diffuse large B-cell lymphoma

- 1. Department of Hematology, Fujian Provincial Hospital, Fuzhou, 350001, China;
- 2. Department of Pathology, Fujian Provincial Hospital

More Information

Corresponding author: CHEN Weimin, E-mail: chenweiming@medmail.com.cn

Received Date: 20 July 2011

摘要

摘要: 目的:探讨Ki-67蛋白在弥漫大B细胞淋巴瘤(DLBCL)组织中的表达情况及其对患者预后的意义。方法:采用EliVision plus免疫组织化学二步法测定85例DLBCL患者肿瘤组织中Ki-67蛋白的表达,前瞻性调查分析其与临床特征及疗效的关系。结果:85例DLBCL患者中36例(42.4%)肿瘤组织呈Ki-67蛋白高表达。Non-GCB组Ki-67高表达率为56.1%,GCB组Ki-67高表达率为29.5%,差异有统计学意义(P＜0.05)。中位随访24个月后,生存分析显示Ki-67高表达组中位疾病无进展生存时间(PFS)为18个月,短于Ki-67低表达组31个月,两组PFS差异有统计学意义(P＜0.05)。Ki-67高表达组接受R-CHOP方案化疗PFS长于CHOP方案组,差异有统计学意义(P＜0.05),在Ki-67低表达组未观察到两种化疗方案PFS差异有统计学意义(P＞0.05)。结论:Ki-67对判断弥漫大B细胞淋巴瘤预后及选择治疗方案均有较好的指导意义。
- 淋巴瘤 /
- Ki-67 /
- 免疫组织化学 /
- 化疗 /
- 预后
Abstract: Objective:To evaluate the expression of Ki-67 protein in patients with diffuse large B-cell lymphoma (DLBCL) so as to analyze the clinical utility of Ki-67 for predicting prognosis. Method:The expression of Ki-67 was measured in 85 patients with DLBCL by EliVision plus method.Its relationship to clinical feature and prognosis was studied.Result:High-level expression of Ki-67 was found in 36(42.4%) of the 85 DLBCL patients.The high Ki-67 expression rate in non-GCB group was higher than that in GCB group(56.1% vs 29.5%,P＜0.05).The median of 24-months follow-up research revealed that progression-free survival (PFS) was significantly lower (P＜0.05) in the high Ki-67 expression group than in the low Ki-67 expression group (median,18 vs 31 months).Patients with high Ki-67 expression had lower PFS(P＜0.05) when they were treated with R-CHOP regiment compared with standard CHOP regiment.On the other hand,PFS was similar between R-CHOP and CHOP groups in patients with low Ki-67 expression (P＞0.05).Conclusion:Ki-67 can be used for predicting prognosis in patients with DLBCL. High Ki-67 expression is associated with non-GCB immunology type of DLBCL and poor survival .R-CHOP might be preferable to CHOP in patients with high Ki-67 expression.
- lymphoma /
- Ki-67 /
- immunohistochemistry /
- chemotherapy /
- prognosis

HTML全文

参考文献(19)

[1]	陈愉,蒋会勇,朱梅刚,等.弥漫性大B细胞淋巴瘤CD10、bcl-6、MUM1蛋白表达与分子分型[J].中华血液学杂志,2005,26(10):51-52.
[2]	[KG*1]ZELENETZ A D,ABRAMSON J S,ADVANI R H,et al.NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas[J].J Natl Compr Canc Netw, 2010, 8: 288-334.
[3]	[KG*1]YOON D H,CHOI D R,AHN H J,et al.Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP[J].Eur J Haematol, 2010, 85: 149-157.
[4]	[KG*1]HANS C P,WEIS D D,GREINER T C,et al.Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J].Blood, 2004, 103: 275-282.
[5]	[KG*1]张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:19-23.
[6]	[KG*1]MORENTE M M,PIRIS M A,ABRAIRA V,et al.Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression,high Ki67 proliferation index,and absence of Epstein-Barr virus-latent membrane protein 1 expression[J].Blood,1997,90:2429-2436.
[7]	[KG*1] KIM S J,KIM B S,CHOI C W,et al.Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma,nasal type[J].Ann Oncol,2007,18:1382-1387.
[8]	[KG*1]NCCN非霍奇金淋巴瘤临床实践指南( 中国版)专家组.2009年NCCN非霍奇金淋巴瘤临床实践指南(中国版)[EB/OL].http://www.nccn-china.org/2009.
[9]	[KG*1]张文书,杨庆春,张望望,等.p53、Ki-67在弥漫性大B细胞淋巴瘤中的表达及相互关系[J].肿瘤防治研究, 2007,34(12): 914-916.
[10]	宋恩霖,熊小亮,艾有生,等.Ki-67在GCB及non-GCB弥漫性大B细胞淋巴瘤中的表达及意义[J].江西医药,2011,(2):111-114.
[11]	OSCHLIES I,KLAPPER W,ZIMMERMANN M,et al.Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial[J].Blood,2006,107: 4047-4052.
[12]	WANG M J,PEI D S,QIAN G W,et al.p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells [J].Tumour Biol,2011,32:905-912.
[13]	陈振文,王晋芬,王国平,等.3q27-3q29相关的p63蛋白表达在弥漫性大B细胞淋巴瘤中的意义[J].白血病·淋巴瘤,2010,19(3): 161-165.
[14]	刘艳艳,姚书娜,姚志华,等.p53突变蛋白表达对弥漫大B细胞淋巴瘤预后的预测作用[J].白血病·淋巴瘤,2011,20(8): 468-470.
[15]	吕方芳,陆洪芬,印季良,等.survivin、bcl-2及ki-67在弥漫大B细胞淋巴瘤中的表达及临床意义[J].肿瘤,2006,26(10):930-934.
[16]	夏海龙,王志国,陈冰,等.BCL-2、Ki-67、CyclinD1在弥漫性大B细胞淋巴瘤中表达的临床意义[J].中国组织化学与细胞化学杂志,2005,14(3):335-338.
[17]	刘勇,路名芝,张文书.弥漫性大B细胞淋巴瘤不同免疫类型中bcl-2、Ki-67的表达及相互关系[J].临床与实验病理学杂志,2007,23(3):369-370.
[18]	ZHENG J N,SUN Y F,PEI D S,et al.Treatment with vector-expressed small hairpin RNAs against Ki67 RNA-induced cell growth inhibition and apoptosis in human renal carcinoma cells [J].Acta Biochim Biophys Sin (Shanghai),2006,38:254-261.
[19]	毛立军,郑骏年,郑宏祥,等.Ki67基因RNA干扰增殖型腺病毒对肺癌细胞增殖的抑制作用[J].肿瘤防治研究,2007,34(4):262-265.